Intellia Therapeutics Inc logo

Intellia Therapeutics Inc

$ 53.92 -3.16 (-5.54%) 10:08 PM EST
P/E:
At Loss
P/B:
4.65
Market Cap:
$ 4.10B
Enterprise V:
$ 3.29B
Volume:
1.65M
Avg Vol (2M):
1.22M
Also Trade In:
Volume:
1.65M
Market Cap $:
4.10B
PE Ratio:
At Loss
Avg Vol (2-Month):
1.22M
Enterprise Value $:
3.29B
PB Ratio:
4.65
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Name Current Vs Industry Vs History
Cash-To-Debt 12.57
Equity-to-Asset 0.79
Debt-to-Equity 0.08
Debt-to-EBITDA -0.18
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 9.18
Distress
Grey
Safe
Beneish M-Score -1.98
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 19.37
9-Day RSI 31.77
14-Day RSI 38.24
6-1 Month Momentum % -13.78
12-1 Month Momentum % -60.99

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 7.24
Quick Ratio 7.24
Cash Ratio 7.06
Days Sales Outstanding 17.98

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -19.6

Financials (Next Earnings Date:2022-11-04 Est.)

NTLA's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:NTLA

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 45.34
EPS (TTM) ($) -5.35
Beta 1.72
Volatility % 57.18
14-Day RSI 38.24
14-Day ATR ($) 4.459304
20-Day SMA ($) 60.7915
12-1 Month Momentum % -60.99
52-Week Range ($) 37.08 - 154.1499
Shares Outstanding (Mil) 76.01

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Intellia Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Intellia Therapeutics Inc Analysis

Share your research

Headlines

See More
No news.